Evidence map›Paper›PMID 34727945›Full record

ArticleCancer cell international2021

Effect of PLC-β1/CaM signaling pathway mediated by AT1R on the occurrence and development of hepatocellular carcinoma.

Zhou-Wei Xu, Na-Na Liu, Xing-Yu Wang, Bai-Cheng Ding, Hai-Feng Zhang, Ying Li, Wu-Yi Sun, Wei Wei

Abstract read
In one paragraph

Article in Cancer cell international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhou-Wei XuDepartment of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Road, Hefei, 230022, Anhui, People's Republic of China.
Na-Na LiuDepartment of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Road, Hefei, 230022, Anhui, People's Republic of China.
Xing-Yu WangDepartment of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Road, Hefei, 230022, Anhui, People's Republic of China.
Bai-Cheng DingDepartment of Emergency Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Road, Hefei, 230022, Anhui, People's Republic of China.
Hai-Feng ZhangDepartment of Clinical Medical, the First Clinical Medical College of Anhui Medical University, Meishan Road, Hefei, 230032, Anhui, People's Republic of China.
Ying LiKey Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road, Hefei, 230032, Anhui, People's Republic of China.
Wu-Yi SunKey Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road, Hefei, 230032, Anhui, People's Republic of China. sunwuyi@ahmu.edu.cn.ORCID http://orcid.org/0000-0002-6233-2356
Wei WeiKey Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Center of Anti-Inflammatory and Immune Medicine, Institute of Clinical Pharmacology, Anhui Medical University, Meishan Road, Hefei, 230032, Anhui, People's Republic of China. wwei@ahmu.edu.cn.

Funding

national natural science foundation of china 81673444the open fund of key laboratory of anti-inflammatory and immune medicine, ministry of education KFJJ-2020-02the school fund of anhui medical university 2020xkj177
6 · The paper itself

Abstract

objectiveTo study the roles of AT1R, PLC-β1, CaM and other related signal molecules in the formation and development of hepatocellular carcinoma (HCC) and their correlation.

methodsELISA and immunohistochemistry were used to analyze the expressions of target proteins in serum and liver tissue of HCC patients, and the correlation between AT1R, PLC-β1 and CaM and postoperative survival status of patients was followed up and determined. CCK-8 method was used to screen the doses of Ang II and candesartan sensitive to HepG2 and HCCLM3 cells. Transwell experiment was used to observe the effects of different drugs on the migration and invasion activity of HCC cells. Meanwhile, flow cytometry and Western blot were used to detect the expression levels of AT1R, PLC-β1 and CaM in the cells. Then PLC-β1 siRNA was selected to transfect HCC cells, so as to further clarify the mechanism of the above signal proteins. HepG2 cells were inoculated under the hepatic capsule of mice to induce the formation of HCC in situ. Ang II and candesartan were used to stimulate HCC mice to observe the difference in liver appearance and measure the liver index. Finally, ELISA and immunofluorescence experiments were selected to analyze the levels of target proteins in mouse serum and liver tissue.

resultsThe expression levels of target proteins in serum and liver tissue of HCC patients were significantly increased, and the postoperative survival time of patients with high expression of AT1R, PLC-β1 or CaM was obviously shortened. Ang II and candesartan could significantly promote and inhibit the motility of HCC cells, and had different effects on the levels of AT1R, PLC-β1 and CaM in cells. However, in hepatocellular carcinoma cells transfected with PLC-β1 siRNA, the intervention ability of drugs was obviously weakened. Ang II could significantly promote the formation and progression of mouse HCC, while candesartan had the opposite effect. Meanwhile, medications could affect the expressions of target proteins in mouse serum and liver tissue.

conclusionAT1R, PLC-β1 and CaM may be risk factors affecting the formation and prognosis of HCC, and the PLC-β1/CaM signaling pathway mediated by AT1R is an important way to regulate the migration and invasion activity of HCC cells.

Indexed as

AT1RCaMHepatocellular carcinomaInvasionMigrationPLC-β1

Identifiers

PMID34727945
PMCPMC8561349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.